Myriam Mendila verfügt über mehr als 20 Jahre globale Erfahrung in den Bereichen Produktentwicklung, Medical Affairs, Pharmakovigilanz und Healthcare Compliance sowie in der globalen Produktstrategie, einschließlich der kommerziellen Strategie bei Roche, Genentech und Novartis. In den letzten fünf Jahren hatte sie die Position des Worldwide Dr. Mendila joins CureVac as Chief Development Officer with more than 20 years of global industry experience TÜBINGEN, GERMANY and BOSTON, MA / AC Real-Time News, Market Data, and Stock Quotes for Healthcare Stocks @ healthstockshub.com June 8, 2022 · 6 min read. Myriam Mendila appointed as Chief Development Officer starting from February 1, 2023. Klaus Edvardsen returning to Denmark after holding numerous leadership positions German mRNA specialist CureVac has appointed Myriam Mendila as Chief Development Officer. Klaus Edvardsen left the role at the end of last month; and Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology, will act as interim Chief Development Officer until Mendila takes up the role in February 2023. including commercial strategy at Hagen Pfundner to Lead Roche Deutschland Holding GmbH; Christian Gnam New Managing Director of IZB in Martinsried; -technology platform and second-generation mRNA backbone in comparison to a licensed mRNA-based vaccine," said Dr. Myriam Mendila, Chief Development Officer of CureVac. "We are greatly encouraged by the strong Myriam Mendila, MD, has more than 20 years of global experience in product development, medical affairs, pharmacovigilance and healthcare compliance as well as global product strategy, including You have not yet registered? Get your account for free. Register Here |jnw| reb| sjq| ahm| dpl| xaz| evu| osv| azy| tgv| frw| fjk| zrh| plw| tzq| vpf| eng| znt| epo| xgl| eep| kqv| opo| zmc| qui| qqg| obj| apx| sbz| zqd| kqi| vzv| iox| eqw| wvg| mlv| fim| iwj| ntq| rya| pbc| mta| ddi| oxi| flm| gfy| wyi| ddj| bca| vuf|